Page last updated: 2024-12-11
auriculasin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
auriculasin: isolated from the fruits of Maclura pomifera; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Maclura | genus | A plant genus of the family MORACEAE. Members contain maclurin, antifungal chalcones, and other compounds.[MeSH] | Moraceae | The mulberry plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. They have milky latex and small, petalless male or female flowers.[MeSH] |
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5358846 |
| CHEMBL ID | 459129 |
| CHEBI ID | 178564 |
| MeSH ID | M0506215 |
Synonyms (18)
| Synonym |
|---|
| CHEBI:178564 |
| 7-(3,4-dihydroxyphenyl)-5-hydroxy-2,2-dimethyl-10-(3-methylbut-2-enyl)pyrano[3,2-g]chromen-6-one |
| cudraisoflavone a |
| NSC285656 , |
| auriculasin |
| 60297-37-2 |
| nsc-285656 |
| CHEMBL459129 |
| LMPK12050247 |
| bdbm50442400 |
| DTXSID50418510 |
| ncgc00384963-01!7-(3,4-dihydroxyphenyl)-5-hydroxy-2,2-dimethyl-10-(3-methylbut-2-enyl)pyrano[3,2-g]chromen-6-one |
| FS-8648 |
| 7-(3,4-dihydroxyphenyl)-5-hydroxy-2,2-dimethyl-10-(3-methyl-2-buten-1-yl)-2h,6h-pyrano[3,2-g]chromen-6-one |
| nsc 285656 |
| HY-N2911 |
| CS-0023510 |
| AKOS040761390 |
Research Excerpts
Effects
| Excerpt | Reference | Relevance |
|---|---|---|
| "Auriculasin has a wide range of pharmacological effects, including anticancer and anti-inflammatory effects. " | ( In Vitro Metabolism of Auriculasin and Its Inhibitory Effects on Human Cytochrome P450 and UDP-Glucuronosyltransferase Enzymes. Ge, G; Guo, Z; Shan, L; Shi, X; Song, Y; Su, D; Zhang, G, 2019) | 2.27 |
| "Auriculasin has a wide range of pharmacological effects, including anticancer and anti-inflammatory effects. " | ( In Vitro Metabolism of Auriculasin and Its Inhibitory Effects on Human Cytochrome P450 and UDP-Glucuronosyltransferase Enzymes. Ge, G; Guo, Z; Shan, L; Shi, X; Song, Y; Su, D; Zhang, G, 2019) | 2.27 |
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Auriculasin treatment resulted in selective apoptotic cell death in LNCaP prostate cancer cells, characterized by DNA fragmentation, accumulation of sub-G1 cell population, cleavage of poly (ADP-ribose) polymerase (PARP), regulation of Bax/Bcl-2 ratio, increase of cytosolic apoptosis-inducing factor (AIF) and endonuclease G (EndoG), in addition to inhibiting tumor growth in a xenograft mouse model." | ( Auriculasin-induced ROS causes prostate cancer cell death via induction of apoptosis. Cho, HD; Lee, JH; Lee, MK; Moon, KD; Park, KH; Seo, KI, 2018) | 2.64 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| isoflavanones | Members of the class of isoflavans that have a 3,4-dihydro-3-aryl-2H-1-benzopyran-4-one skeleton and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (3)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Plasma kallikrein | Homo sapiens (human) | Ki | 4.4000 | 0.0002 | 3.3474 | 9.6000 | AID1271911 |
| Sialidase | Clostridium perfringens | IC50 (µMol) | 0.3000 | 0.0010 | 2.4572 | 9.8000 | AID779446 |
| Sialidase | Clostridium perfringens | Ki | 0.1300 | 0.1030 | 1.9784 | 7.4100 | AID779447 |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | IC50 (µMol) | 3.6000 | 0.0005 | 3.4984 | 9.7600 | AID1271910 |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | Ki | 4.4000 | 0.1900 | 4.8327 | 9.6000 | AID1271911 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (34)
Molecular Functions (13)
Ceullar Components (14)
Bioassays (15)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID354483 | Inhibition of DMBA-induced/TPA-promoted carcinogenesis in ICR mouse assessed as mouse bearing papillomas at 85 nmol administered 1 hr before TPA treatment measured after 8 weeks | 2004 | Journal of natural products, Jul, Volume: 67, Issue:7 | Chemical constituents of Millettia taiwaniana: structure elucidation of five new isoflavonoids and their cancer chemopreventive activity. |
| AID1271910 | Inhibition of human recombinant PTP1B using p-nitrophenyl phosphate as substrate by spectrophotometric analysis | 2016 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2 | Novel chromenedione derivatives displaying inhibition of protein tyrosine phosphatase 1B (PTP1B) from Flemingia philippinensis. |
| AID1385658 | Antibacterial activity against Staphylococcus aureus TISTR 1466 by 2-fold serial dilution method | 2018 | Journal of natural products, 08-24, Volume: 81, Issue:8 | Antibacterial Prenylated Isoflavonoids from the Stems of Millettia extensa. |
| AID354482 | Inhibition of DMBA-induced/TPA-promoted carcinogenesis in ICR mouse assessed as number of skin papillomas per mouse at 85 nmol administered 1 hr before TPA treatment measured after 20 weeks | 2004 | Journal of natural products, Jul, Volume: 67, Issue:7 | Chemical constituents of Millettia taiwaniana: structure elucidation of five new isoflavonoids and their cancer chemopreventive activity. |
| AID779447 | Non-competitive inhibition of Clostridium perfringens neuraminidase using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid sodium salt hydrate as substrate by Dixon plot method | 2013 | Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21 | Bacterial neuraminidase inhibitory effects of prenylated isoflavones from roots of Flemingia philippinensis. |
| AID1385661 | Antibacterial activity against Pseudomonas aeruginosa TISTR 292 by 2-fold serial dilution method | 2018 | Journal of natural products, 08-24, Volume: 81, Issue:8 | Antibacterial Prenylated Isoflavonoids from the Stems of Millettia extensa. |
| AID779446 | Inhibition of Clostridium perfringens neuraminidase using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid sodium salt hydrate as substrate by fluorimetry | 2013 | Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21 | Bacterial neuraminidase inhibitory effects of prenylated isoflavones from roots of Flemingia philippinensis. |
| AID354487 | Inhibition of DMBA-induced/TPA-promoted carcinogenesis in ICR mouse assessed as number of skin papillomas per mouse at 85 nmol administered 1 hr before TPA treatment measured after 17 weeks | 2004 | Journal of natural products, Jul, Volume: 67, Issue:7 | Chemical constituents of Millettia taiwaniana: structure elucidation of five new isoflavonoids and their cancer chemopreventive activity. |
| AID1271911 | Non-competitive inhibition of human recombinant PTP1B using p-nitrophenyl phosphate as substrate by spectrophotometry based Lineweaver-Burk plot | 2016 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2 | Novel chromenedione derivatives displaying inhibition of protein tyrosine phosphatase 1B (PTP1B) from Flemingia philippinensis. |
| AID1385659 | Antibacterial activity against Staphylococcus epidermidis ATCC 12228 by 2-fold serial dilution method | 2018 | Journal of natural products, 08-24, Volume: 81, Issue:8 | Antibacterial Prenylated Isoflavonoids from the Stems of Millettia extensa. |
| AID1385657 | Antibacterial activity against Bacillus subtilis TISTR 008 by 2-fold serial dilution method | 2018 | Journal of natural products, 08-24, Volume: 81, Issue:8 | Antibacterial Prenylated Isoflavonoids from the Stems of Millettia extensa. |
| AID354486 | Inhibition of DMBA-induced/TPA-promoted carcinogenesis in ICR mouse assessed as number of skin papillomas per mouse at 85 nmol administered 1 hr before TPA treatment measured after 14 weeks | 2004 | Journal of natural products, Jul, Volume: 67, Issue:7 | Chemical constituents of Millettia taiwaniana: structure elucidation of five new isoflavonoids and their cancer chemopreventive activity. |
| AID354485 | Inhibition of DMBA-induced/TPA-promoted carcinogenesis in ICR mouse assessed as mouse bearing papillomas at 85 nmol administered 1 hr before TPA treatment measured after 20 weeks | 2004 | Journal of natural products, Jul, Volume: 67, Issue:7 | Chemical constituents of Millettia taiwaniana: structure elucidation of five new isoflavonoids and their cancer chemopreventive activity. |
| AID354484 | Inhibition of DMBA-induced/TPA-promoted carcinogenesis in ICR mouse assessed as mouse bearing papillomas at 85 nmol administered 1 hr before TPA treatment measured after 10 weeks | 2004 | Journal of natural products, Jul, Volume: 67, Issue:7 | Chemical constituents of Millettia taiwaniana: structure elucidation of five new isoflavonoids and their cancer chemopreventive activity. |
| AID1385660 | Antibacterial activity against Salmonella typhimurium TISTR 781 by 2-fold serial dilution method | 2018 | Journal of natural products, 08-24, Volume: 81, Issue:8 | Antibacterial Prenylated Isoflavonoids from the Stems of Millettia extensa. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (14)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 20.13
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.13) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (7.14%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (92.86%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||